{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":1,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"b86de379d351","filters":{"venue":"Journal of Current Oncology"}},"results":[{"id":"W2889732036","doi":"10.4103/jco.jco_3_18","title":"Response to osimertinib in EGF816-resistant T790M-mutated lung cancer","year":2018,"lang":"en","type":"article","venue":"Journal of Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Osimertinib; T790M; Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Adenocarcinoma; Tyrosine-kinase inhibitor; Internal medicine; Tyrosine kinase; Cancer research; Gefitinib; Cancer; Receptor; Erlotinib","authors":[{"name":"JamesC Kuo","is_ca":true},{"name":"NatashaB Leighl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04712176482318364,"gpt":0.4887936186369286,"spread":0.441671853813745,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001422545,0.0001966643,0.0004064747,0.0001923237,0.0003026002,0.0002408084,0.0001670687,0.0005659957,0.0004528359],"category_scores_gemma":[0.0003685917,0.00007565473,0.0002542875,0.0001434891,0.000170227,0.0001547542,0.0001124826,0.0007552293,0.0001568929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004748206,"about_ca_system_score_gemma":0.0001585866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007129014,"about_ca_topic_score_gemma":0.00208882,"domain_scores_codex":[0.9999245,0.00001149704,0.00000797452,0.00001564401,0.00001353297,0.00002678452],"domain_scores_gemma":[0.9998497,0.00003703573,0.00001890695,0.000007745239,0.00001154561,0.00007500699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"case_report","study_design_scores_codex":[0.00940142,0.001988288,0.09699966,0.0002796067,0.0001795048,0.6366296,0.0007818891,0.002610832,0.1089898,0.0005980806,0.003431595,0.1381096],"study_design_scores_gemma":[0.0008498515,0.03309811,0.2825684,0.00008913551,0.000338807,0.60696,0.0004727822,0.009906445,0.05062493,0.0007778286,0.01423807,0.00007563137],"study_design_candidate":"case_report","study_design_consensus":"case_report","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949604,0.001581957,0.000298084,0.000710722,0.00004912847,0.00003899539,0.00007044795,0.00002415052,0.00226614],"genre_scores_gemma":[0.9987557,0.0002973277,0.00009104332,0.000219196,0.00002658632,0.000003794395,0.00007957557,0.000003230516,0.0005235825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007129014,"threshold_uncertainty_score":0.003445089,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}